Understanding the molecular intricacies associated with MT‐ND4‐expressing CD8+ T cells could unveil novel therapeutic targets aimed at mitigating metastatic progression in ccRCC patients. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.